GlassScriptPhysician profile
Stephannie E Cloninger-Hultz
NPI 1265063192
$5,273.88
in general payments reported to CMS, 2019-2025
39 companies · $20.38 in 2025
The $20.38 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,023 · 2022: $1,351 · 2023: $1,786 · 2024: $1,094 · 2025: $20.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,900.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,428.41 | 2021-2025 | |
| Lilly USA, LLC | $700.50 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $410.84 | 2021-2024 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $294.20 | 2021-2024 | Ozempic, Rybelsus |
| Corcept Therapeutics | $247.81 | 2023-2024 | Korlym |
| Abbott Laboratories | $235.30 | 2021-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.72 | 2022-2024 | Xifaxan |
| Insulet Corporation | $161.15 | 2022-2024 | Omnipod |
| Merck Sharp & Dohme LLC | $143.63 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $130.22 | 2021-2023 | Farxiga, Fasenra |
| Amarin Pharma, INC. | $123.67 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $84.20 | 2023-2024 | Recorlev, Gvoke Hypopen, Keveyis |
| Medtronic, INC. | $82.97 | 2021-2023 | Vanta Adaptivestim, Intellis Adaptivestim |
| Organon LLC | $78.43 | 2021-2023 | Nexplanon |
| Nestle Healthcare Nutrition INC. | $76.76 | 2021-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephannie Cloninger-Hultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.